Aisling M. Rehill

Aisling M. Rehill

Auto-generated profile, based on publicly available information

Aisling M. Rehill

Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TRTristram A. J. Ryan
Tristram A. J. Ryan
AHAlexander Hooftman
Alexander Hooftman
ARAisling M. Rehill
Aisling M. Rehill
Matt JohansenMatt Johansen
Matt Johansen
EBEóin C. O’ Brien
Eóin C. O’ Brien
Luke O'NeillLuke O'Neill
Luke O'Neill
Excessive inflammation-associated coagulation is a feature of infectious diseases, occurring in such conditions as bacterial sepsis and COVID-19. It can lead to disseminated intravascular coagulation, one of the leading causes of mortality worldwide. Recently, type I interferon (IFN) signaling has been shown to be required for tissue factor (TF; gene name F3) release from macrophages, a critical initiator of coagulation, providing an important mechanistic link between innate immunity and coagulation. The mechanism of release involves type I IFN-induced caspase-11 which promotes macrophage pyroptosis. Here we find that F3 is a type I IFN-stimulated gene. Furthermore, F3 induction by lipopolysaccharide (LPS) is inhibited by the anti-inflammatory agents dimethyl fumarate (DMF) and 4-octyl itaconate (4-OI). Mechanistically, inhibition of F3 by DMF and 4-OI involves suppression of Ifnb1 expression. Additionally, they block type I IFN- and caspase-11-mediated macrophage pyroptosis, and subsequent TF release. Thereby, DMF and 4-OI inhibit TF-dependent thrombin generation. In vivo, DMF and 4-OI suppress TF-dependent thrombin generation, pulmonary thromboinflammation, and lethality induced by LPS, E. coli, and S. aureus, with 4-OI additionally attenuating inflammation-associated coagulation in a model of SARS-CoV-2 infection. Our results identify the clinically approved drug DMF and the pre-clinical tool compound 4-OI as anticoagulants that inhibit TF-mediated coagulopathy via inhibition of the macrophage type I IFN-TF axis.

4 August 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
HFHelen Fogarty
Helen Fogarty
SWSoracha E. Ward
Soracha E. Ward
LTLiam Townsend
Liam Townsend
EKEllie Karampini
Ellie Karampini
SEStephanie Elliott
Stephanie Elliott
JFJudicael Fazavana
Judicael Fazavana
Prolonged recovery is common after acute SARS‐CoV‐2 infection; however, the pathophysiological mechanisms underpinning Long COVID syndrome remain unknown. VWF/ADAMTS‐13 imbalance, dysregulated angiogenesis, and immunothrombosis are hallmarks of acute COVID‐19. We hypothesized that VWF/ADAMTS‐13 imbalance persists in convalescence together with endothelial cell (EC) activation and angiogenic disturbance. Additionally, we postulate that ongoing immune cell dysfunction may be linked to sustained EC and coagulation activation. Fifty patients were reviewed at a minimum of 6 weeks following acute COVID‐19. ADAMTS‐13, Weibel Palade Body (WPB) proteins, and angiogenesis‐related proteins were assessed and clinical evaluation and immunophenotyping performed. Comparisons were made with healthy controls (n = 20) and acute COVID‐19 patients (n = 36). ADAMTS‐13 levels were reduced (p = 0.009) and the VWF‐ADAMTS‐13 ratio was increased in convalescence (p = 0.0004). Levels of platelet factor 4 (PF4), a putative protector of VWF, were also elevated (p = 0.0001). A non‐significant increase in WPB proteins Angiopoietin‐2 (Ang‐2) and Osteoprotegerin (OPG) was observed in convalescent patients and WPB markers correlated with EC parameters. Enhanced expression of 21 angiogenesis‐related proteins was observed in convalescent COVID‐19. Finally, immunophenotyping revealed significantly elevated intermediate monocytes and activated CD4+ and CD8+ T cells in convalescence, which correlated with thrombin generation and endotheliopathy markers, respectively. Our data provide insights into sustained EC activation, dysregulated angiogenesis, and VWF/ADAMTS‐13 axis imbalance in convalescent COVID‐19. In keeping with the pivotal role of immunothrombosis in acute COVID‐19, our findings support the hypothesis that abnormal T cell and monocyte populations may be important in the context of persistent EC activation and hemostatic dysfunction during convalescence.

28 March 2024 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
DNDavid Noone
David Noone
RPRoger J.S. Preston
Roger J.S. Preston
ARAisling M. Rehill
Aisling M. Rehill
Inflammation contributes to the development of thrombosis, but the mechanistic basis for this association remains poorly understood. Innate immune responses and coagulation pathways are activated in parallel following infection or injury, and represent an important host defense mechanism to limit pathogen spread in the bloodstream. However, dysregulated proinflammatory activity is implicated in the progression of venous thromboembolism and arterial thrombosis. In this review, we focus on the role of myeloid cells in propagating thromboinflammation in acute inflammatory conditions, such as sepsis and coronavirus disease 2019 (COVID-19), and chronic inflammatory conditions, such as obesity, atherosclerosis, and inflammatory bowel disease. Myeloid cells are considered key drivers of thromboinflammation via upregulated tissue factor activity, formation of neutrophil extracellular traps (NETs), contact pathway activation, and aberrant coagulation factor–mediated protease-activated receptor (PAR) signaling. We discuss how strategies to target the intersection between myeloid cell–mediated inflammation and activation of blood coagulation represent an exciting new approach to combat immunothrombosis. Specifically, repurposed anti-inflammatory drugs, immunometabolic regulators, and NETosis inhibitors present opportunities that have the potential to dampen immunothrombotic activity without interfering with hemostasis. Such therapies could have far-reaching benefits for patient care across many thromboinflammatory conditions.

7 March 2025 in Science Advances
Verified
Journal Article
Open access
ARAisling M. Rehill
Aisling M. Rehill
SMSeán McCluskey
Seán McCluskey
ALAnna E. Ledwith
Anna E. Ledwith
TRTristram A. J. Ryan
Tristram A. J. Ryan
BÜBetül Ünlü
Betül Ünlü
RPRoger J. S. Preston
Roger J. S. Preston
The pathogenic basis for increased thrombotic risk in individuals with inflammatory diseases is poorly understood. Myeloid cell “trained immunity” describes persistent innate immune cell memory arising from prior exposure to an inflammatory stimulus, leading to an enhanced immune response to subsequent unrelated stimuli. We identify enhanced myeloid cell prothrombotic activity as a maladaptive consequence of trained immunity. Lipopolysaccharide (LPS) stimulation of macrophages trained previously with β-glucan or heme exhibited significantly enhanced procoagulant activity compared to macrophages stimulated with LPS alone, which was mediated by enhanced acid sphingomyelinase–mediated tissue factor decryption. Furthermore, splenic monocytes isolated from β-glucan–trained mice revealed enhanced procoagulant activity up to 4 weeks after β-glucan administration compared to monocytes from control mice over the same time period. Moreover, hematopoietic progenitor cells and bone marrow interstitial fluid from β-glucan–trained mice had enhanced procoagulant activity compared to control mice. Trained immunity and associated metabolic perturbations may therefore represent an opportunity for targeted intervention in immunothrombotic disease development.

11 November 2023 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
TRT. Ryan
T. Ryan
AHAlexander Hooftman
Alexander Hooftman
ARA. Rehill
A. Rehill
MJM. Johansen
M. Johansen
EOE. O’bRien
E. O’bRien
LOL. O’nEill
L. O’nEill

21 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAisling M. Rehill
Aisling M. Rehill
GLGemma Leon
Gemma Leon
SMSean McCluskey
Sean McCluskey
ISIngmar Schoen
Ingmar Schoen
YHYasmina Hernandez-Santana
Yasmina Hernandez-Santana
RPRoger J.S. Preston
Roger J.S. Preston
Background: Myeloid cell metabolic reprogramming is a hallmark of inflammatory disease, however, its role in inflammation-induced hypercoagulability is poorly understood. Objective/Methods: Using novel myeloid cell-based global haemostasis assays and murine models of immunometabolic disease, we evaluated the role of inflammation-associated metabolic reprogramming in regulating blood coagulation. Results: Glycolysis was essential for enhanced activated myeloid cell tissue factor expression and decryption, driving increased cell-dependent thrombin generation in response to inflammatory challenge. Similarly, inhibition of glycolysis enhanced activated macrophage fibrinolytic activity via reduced plasminogen activator inhibitor 1 (PAI-1)-activity. Macrophage polarisation or activation markedly increased endothelial protein C receptor (EPCR) expression on monocytes and macrophages, leading to increased myeloid cell-dependent protein C activation. Importantly, inflammation-dependent EPCR expression on tissue-resident macrophages was also observed in vivo . Adipose tissue macrophages from obese mice fed a high-fat diet exhibited significantly enhanced EPCR expression and APC generation compared to macrophages isolated from the adipose tissue of healthy mice. Similarly, the induction of colitis in mice prompted infiltration of EPCR + innate myeloid cells within inflamed colonic tissue that were absent from the intestinal tissue of healthy mice. Conclusion: Collectively, this study identifies immunometabolic regulation of myeloid cell hypercoagulability, opening new therapeutic possibilities for targeted mitigation of thrombo-inflammatory disease. ESSENTIALS: Inflammation-mediated glycolytic reprogramming enables myeloid cell-induced hypercoagulability and antifibrinolytic activity. 2-Deoxy-D-glucose (2-DG) inhibits the expression of transcription factors necessary for inflammation-induced procoagulant gene expression. Myeloid cell membrane regulation of tissue factor procoagulant activity is glycolysis-dependent. Activation of myeloid innate immunity dysregulates activated protein C anticoagulant pathway activity.